预测结直肠癌肝转移患者肝切除术后癌症复发的转录组特征
研究对383例结直肠癌肝转移(CRLM)患者进行全基因组表达谱分析,识别并验证了一个六基因组合特征。该特征在发现集、训练集和验证集中均能预测复发,与关键临床因素联合建立的风险分层模型为复发的独立预测因子。
要点
- 六基因组合特征在发现集AUC=0.90,训练集AUC=0.83,验证集AUC=0.81。
- 风险分层模型为复发独立预测因子:单因素HR=4.34(95%CI 2.71-6.93,P<0.001),多因素HR=3.40(95%CI 1.76-6.56,P<0.001)。
- 分层模型在高危组中预测89%复发,在低危组中预测62%无复发。
核心结论
- 建立了一个新型转录组特征,能稳健预测CRLM患者肝切除术后的复发,对患者管理有重要意义。
研究设计与样本
- 研究分析了383例CRLM患者,包括来自NCBI基因表达综合数据库(GSE81423)的63例公开数据,以及收集手术标本的320例患者用于独立训练(n=169)和验证(n=151)所识别的生物标志物。
- 采用Cox比例风险回归分析评估所识别基因特征的临床意义,并与多个关键临床因素比较性能。
主要发现
- 识别了一个六基因组合,在发现集中稳健区分复发患者(AUC=0.90)。
- 该组合在临床训练集(AUC=0.83)和验证集(AUC=0.81)中均为复发的显著预测因子。
- 将组合与关键临床因素联合建立的风险分层模型为复发的独立预测因子(AUC=0.85;单因素:HR=4.34,95%CI=2.71-6.93,P<0.001;多因素:HR=3.40,95%CI=1.76-6.56,P<0.001)。
- 分层模型在高危组中预测89%复发,在低危组中预测62%无复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer recurrence is an important predictor of survival outcomes in patients with colorectal cancer-associated liver metastasis (CRLM), who undergo radical hepatectomy. Therefore, identification of patients with the greatest risk of recurrence is critical for developing a precision oncology strategy that might include frequent surveillance (in low-risk patients) or a more aggressive treatment approach (in high-risk patients). We performed genome-wide expression profiling, to identify and develop a transcriptomic signature for predicting recurrence in patients with CRLM. METHODS: We analysed a total of 383 patients with CRLM, including 63 patients from a publicly available data set (the NCBI's Gene Expression Omnibus with accession number GSE81423). and 320 patients from whom surgical specimens were collected for independent training (n = 169) and validation (n = 151) of identified biomarkers. Using Cox's proportional hazard regression analysis, we evaluated the clinical significance of the identified gene signature by comparing its performance with several key clinical factors. RESULTS: We identified a six-gene panel that robustly categorised patients with recurrence in the discovery (area under the curve (AUC) = 0.90). We showed that the panel was a significant predictor of recurrence in the clinical training (AUC = 0.83) and validation cohorts (AUC = 0.81). By combining our panel with key clinical factors, we established a risk-stratification model that emerged as an independent predictor of recurrence (AUC = 0.85; univariate: hazard ratio (HR) = 4.34, 95% confidence interval (CI) = 2.71-6.93, P < 0.001; multivariate: HR = 3.40, 95% CI = 1.76-6.56, P < 0.001). The stratification model revealed recurrence prediction in 89% of high-risk group and non-recurrence in 62% of low-risk group. CONCLUSIONS: We established a novel transcriptomic signature that robustly predicts recurrence, which has significant implications for the management of patients with CRLM.
引用
- Wada Y, Shimada M, Morine Y, et al. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases. Eur J Cancer. 2022. PMID: 35042069. doi:10.1016/j.ejca.2021.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。